Fax: (713) 745-4612
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia†
Article first published online: 18 MAR 2003
Copyright © 2003 American Cancer Society
Volume 97, Issue 7, pages 1721–1731, 1 April 2003
How to Cite
Tsimberidou, A.-M., Stavroyianni, N., Viniou, N., Papaioannou, M., Tiniakou, M., Marinakis, T., Skandali, A., Sakellari, I. and Yataganas, X. (2003), Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer, 97: 1721–1731. doi: 10.1002/cncr.11240
The following Hospitals and Physicians participated in the study: First Department of Internal Medicine, National University of Athens, Medical School, “Laiko” General Hospital (D. Loukopoulos, A. M. Tsimberidou, N. Viniou, N. Stavroyianni, J. Meletis, C. Constantopoulos, E. Variami, T. Andreopoulos, Y. Rombos, and X. Yataganas); Department of Clinical Propedeutic National University of Athens Medical School, “Laiko” General Hospital (P. Panagiotidis); Second Department of Internal Medicine, National University of Athens Medical School, Hippokration General Hospital (Th. Kalmantis and M. Belegrati); Department of Internal Medicine, Division of Hematology,University Hospital of Patras, Rion-Patras (N. Zoumbos, T. Matsouka, M. Tiniakou, A. Symeonidis, A. Kourakli, and P. Zikos); First Propedeutic Department of Medicine “AHEPA” University Hospital, Thessaloniki (A. Papadopoulos); Department of Hematology, Regional General Hospital of Athens “G. Gennimatas” (T. Marinakis, A. Galanopoulos, E. Michali, and N. Anagnostopoulos); Department of Hematology, “Benizelio” General Hospital, Heraklion, Crete (P. Iliakis); Department of Hematology, “Theagenion” Cancer Center, Thessaloniki (M. Papaioannou, J. Christakis, J. Korantzis, and A. Lazaridou); Department of Hematology, “401” General Army Hospital, Athens (D. Kolokithopoulos and C. Poziopoulos); Department of Hematology, Demokriteion University Hospital of Alexandroupolis, Thrace (G. Bourikas and K. Tsatalas); Department of Hematology, Crete School of Medicine, University Hospital, Heraklion, Crete (G. D. Eliopoulos and H. A. Papadaki); “Metaxa” Cancer Hospital, Athens (C. Megalakaki, B. Seitanidis, and M. Hatziyanni); University of Ioannina Hospital, Ioannina (K. L. Bourantas); Hematology Clinic, “HYGEIA” Diagnostic and Therapeutic Center, Athens (A. Papagiannis, Barbarousi, and G. Karianakis); Hematology Clinic Transplantation Unit, “Evangelismos” General Hospital, Athens (M. Nikiforakis, A. Skandali, N. Charchalakis, and N. Karakasis); Hematology Clinic, Transplantation Unit, “G. Papanikolaou” General Hospital, Thessaloniki (A. Fassas, A. Anagnostopoulos, and I. Sakellari.); and Laboratory of Immunology and Hematology, “G. Gennimatas” General Hospital (A. Tasiopoulou, E. Griva, E. Goumakou, G. Paterakis, G. Stavroupoulou-Giokas, and G. Androutsos).
- Issue published online: 18 MAR 2003
- Article first published online: 18 MAR 2003
- Manuscript Accepted: 2 DEC 2002
- Manuscript Received: 9 OCT 2002
- 8Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML). AML Cooperative Group. Blood. 1995; 86: 434a..
- 15Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998; 351: 700–708., , , et al.
- 28Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217–223., , , et al.
- 32Internatinal System for Human Cytogenetic Nomenclature (ICSN). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, 1995.
- 33National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1988.
- 36Statistical methods for rates and proportions, 2nd edition. New York: John Wiley & Sons, 1981..
- 38Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997; 89: 2311–2318., , , et al.
- 41A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999; 107: 69–79., , , et al.
- 45No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000; 110: 308–314., , , et al.